Abstract. Key words: DNA, Hepatic failure, Immunosuppression, Virology. Introduction
|
|
- Richard Armstrong
- 5 years ago
- Views:
Transcription
1 POSter PreSeNtAtION Epstein-Barr Virus DNAemia in Iranian Liver Transplant Recipients and Assessment of Its Variation in Posttransplant Lymphproliferative Disorder Patients by Quantitative Polymerase Chain Reaction Assay Marzieh Jamalidoust, 1,2 Bita Geramizadeh, 3 Gholamreza Pouladfar, 1 Mandana Namayandeh, 1 Sadaf Asaie, 1 Nasrin Aliabadi, 1 Saman Nikeghbalian, 4 Mazyar Ziyaeyan 1 Abstract Objectives: Epstein-Barr virus primary infection and/or reactivation may play a major role in the incidence of posttransplant lymphoproliferative disorder in organ recipients. We assessed Epstein- Barr virus viral load in liver transplant patients suspected of having Epstein-Barr virus/ post - transplant lymphoproliferative disorder at specified times after transplant and evaluated the clinical findings and posttransplant complications. Materials and Methods: In the 696 patients who underwent liver transplant in this retrospective study, Epstein-Barr virus viral load was examined intermittently in 127 liver transplant recipients who were suspected to have Epstein-Barr virus infection/disease. Sampling was performed during 4 years from July 2009 to May 2013 using real-time polymerase chain reaction assay. Clinical and pathologic data were gathered by reviewing medical records. From the 1 Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Nemazee Hospital, Shiraz; the 2 Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran; the 3 Department of Pathology, Shiraz Medical School, Shiraz University of Medical Sciences, Nemazee Hospital, Shiraz; and the 4 Department of Surgery, Transplant Center, Shiraz University of Medical Sciences, Nemazee Hospital, Shiraz, Iran Acknowledgements: The authors thank Dr. Nasrin Shokrpour at Center for Development of Clinical Research of Nemazee Hospital, Dr. Hassan Khajehei for editorial assistance, and Ms. Roosta for her help with statistical analysis. This study was supported by the Professor Alborzi Clinical Microbiology Research Center Fund. Author contributions: Marzieh Jamalidoust and Mazyar Ziyaeyan designed the study; Marzieh Jamalidoust and Gholamreza Pouladfar wrote the manuscript; Nasrin Aliabadi and Mandana Namayandeh did most of the real-time polymerase chain reaction assays; Sadaf Asaei and Mandana Namayandeh gathered and analyzed the patient information; Bita Geramizadeh detected and analyzed posttransplant lymphproliferative disorder lesions; and Saman Nikeghbalian performed most of the liver surgery. Corresponding author: Mazyar Ziyaeyan, PhD, Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Nemazee Hospital, PO Box , Shiraz, Iran Phone: Fax: ziyaeyanm@sums.ac.ir Experimental and Clinical Transplantation (2015) Suppl 1: Results: There were 78 of the 127 suspected patients (61%) who exhibited Epstein-Barr virus DNAemia and 19 patients had posttransplant lymphoproliferative disorder. The median EBV viral load of posttransplant lymphoproliferative disorder patients was significantly higher than unaffected patients. Posttransplant lymphoproliferative dis - order was diagnosed clinically in 34 subjects (4.9%). Estimated mortality rate of posttransplant lympho - proliferative disorder patients was 35% during 1.5- year follow-up after transplant. Conclusions: Monitoring Epstein-Barr virus load may enable detection of Epstein-Barr virus infection/ disease in liver transplant patients suspected of having the virus, even several weeks before the onset of any clinical manifestations, especially in pediatric patients who have high incidence and mortality from posttransplant lymphoproliferative disorder. Key words: DNA, Hepatic failure, Immunosuppression, Virology Introduction Epstein-Barr virus (EBV) is a member of Herpesviridae family, Gammaherpesvirinae sub - family, and Lymphocryptovirus genus and is known as Human herpesvirus 4. 1,2 It can infect smooth muscle cells, natural killer cells, B lymphocytes, and T lymphocytes. This ubiquitous virus 90% adults worldwide. 3-5 It is associated with different malignancies and disorders such as Hodgkin lymphoma, non-hodgkin lymphoma, Burkitt lymphoma, nasopharyngeal carcinoma, Copyright Başkent University 2015 Printed in Turkey. All Rights Reserved. DOI: /ect.mesot2014.P148
2 Marzieh Jamalidoust et al/experimental and Clinical Transplantation (2015) Suppl 1: gastric carcinoma, and posttransplant lympho pro - liferative disorders (PTLDs). 6,7 In immunocompetent individuals, EBV causes infectious mononucleosis, an acute but self-limited disease that affects children and young adults. Although the severity of infectious mononucleosis is not correlated with EBV viral load, immuno - compromised patients such as patients undergoing organ transplant may have EBV DNAemia that may cause a variety of clinical conditions including a nonspecific viral syndrome, mononucleosis, or PTLD. 8,9 The PTLD is a life-threatening condition that requires urgent treatment and occurs up to 10 years after transplant. 10 The highest morbidity of this complication is within the first year after transplant, with a high incidence in the first 6 months. 11,12 The disease is associated with a wide range of clinical symptoms and may range from a self-restricted proliferation to a severe fulminant disorder. It is classified histologically into 4 groups: (1) early lesions, (2) polymorphic PTLD, (3) monomorphic PTLD, and (4) classic Hodgkin-lymphoma-type PTLD. 3 Based on clinical and histologic features, the diagnosis of PTLD and its differentiation from organ rejection often are difficult, and use of a sensitive test such as real-time polymerase chain reaction (PCR) is recommended The high EBV viral load in the plasma and/or peripheral blood mononuclear cells can serve as a reliable marker for development of PTLD. Different studies show a positive correlation between EBV viral load and severity of PTLD In this study, we quantified the EBV viral load by real-time PCR in patients after liver transplant who were suspected to have EBV/PTLD at the only center for liver transplant in Iran. We report demo - graphic data and outcome of patients associated with PTLD. Materials and Methods Study setting, transplant patients, and samples Medical records of 696 patients who underwent liver transplant at Nemazee Hospital, Shiraz, Iran, from July 2009 to May 2013, were examined retrospectively in this study. Liver transplant accounted for 75% transplants performed during this period at Nemazee Hospital. Routine immuno - suppressive regimen after transplant was triple therapy with tacrolimus, mycophenolate mofetil, and prednisolone. There were 510 specimens in 127 patients that were assessed for EBV DNAemia at Professor Alborzi Clinical Microbiology Research Center, the major referral center for this examination. Sampling time varied in different patients based on clinical manifestations from 1 day to 1.5 years after transplant. Blood samples (average, 4 samples; range, 1-10 samples) were tested for suspected patients. Medical record review showed that 34 patients were affected by PTLD based on clinical data and World Health Organization criteria. 20 Nucleic acid extraction and measurement of epstein-barr virus viral load by real-time polymerase chain reaction Viral DNA was extracted from 200 μl serum by a simple and effective column-based DNA extraction kit (Invisorb Spin Virus DNA Mini Kit, Stratec Biomedical, Birkenfeld, Germany), according to instructions from the manufacturer. Real-time PCR was used as a sensitive and specific method to determine EBV serum sample loads against a serial dilution of a standard that had known EBV DNA content. To quantify EBV DNA, we used a commercially available system (7500 Real-Time PCR System, TaqMan platform, and PrimerDesign kit, Life Technologies, Carlsbad, CA, USA). Each 25λ reaction volume contained: 1 reagent (TaqMan Universal Master Mix), forward and reverse primers (15 pmol each), probe (TaqMan; 10 pmol), 5λ DNA template, and water added up to 25λ. Thermocycling conditions were 50 C for 2 minutes; 95 C for 10 minutes; 95 C for 15 seconds, and 60 C for 1 minute for 40 cycles. The sensitivity of the test was 10 copies/λ specimen. Statistical analyses Data analyses were performed with statistical software (SPSS for Windows, Version 16.0, SPSS Inc., Chicago, IL, USA). Statistical significance was defined by P.05. Results The mean age of 696 patients undergoing liver transplant was ± 0.66 years (range, 1 mo to 75 y). The male: female ratio was 1.74 (442 males;
3 308 Marzieh Jamalidoust et al/experimental and Clinical Transplantation (2015) Suppl 1: Exp Clin Transplant 254 females). Underlying diseases leading to liver transplant were varied, most commonly end-stage hepatitis B virus infection (Figure 1). In 39% patients, the reasons for liver transplant were unknown. Figure 2. Epstein-Barr Virus Load in 8 Patients Who Had Posttransplant Lymphoproliferative Disorder During the Immunosuppression Interval Figure 1. Underlying Disease Leading to Liver Transplantation Abbreviations: AIH, autoimmune hepatitis; HBV, hepatitis B virus; PFIC, progressive familial intrahepatic cholestasis; PSC, primary sclerosing cholangitis The EBV genome was detected in 78 of 127 patients suspected of having EBV/PTLD, including 19 PTLD and 59 non-ptld patients. A significant difference was observed between the median of maximum EBV loads in PTLD patients (4035 copies/ml) and non-ptld patients (500 copies/ml SE ± [standard error]; P.05). Evaluation of the changes in EBV load in 8 PTLD patients (at least 5 measurements per patient) showed that the peak viral load varied between 13 and 360 days after transplant (Figure 2). In the PTLD cases, 13 patients were living and 6 patients died; in the non-ptld patients, 57 patients were living and 2 patients died. A 2-year-old boy with maximum EBV load copies/ml was among the dead non-ptld patients. The incidence of PTLD was 34 patients in 696 transplant patients (4.9%); in 15 patients, there were no medical records with data about EBV load. In the 34 patients, 30 were aged < 12 years (88.2%). Death occurred in 11 of 34 patients (35%) and only 1 patient who died was an adult (Table 1). According to histopathology reports, most lesions in the PTLD patients were not classified (77%) which 1 was associated with non-hodgkin lymphoma (4.3%). Among the classified lesions, 6 were monomorphic PTLD including 5 diffuse large B-cell lymphoma (DLBCL) (22%) and 1 mucosaassociated lymphoid tissue (MALT) B-cell PTLD (4.3%). There was 1 Hodgkin lymphoma PTLD (4.3%), and no patients had polymorphic PTLD or early lesion (Table 1). Discussion There are organ transplants performed annually worldwide, most frequently kidney, liver, lung, and heart transplant in decreasing order of frequency. In our center, the only referral center for liver transplant in Iran, liver transplant is performed more commonly than other organ transplants. Widespread consumption of immuno - modulating agents may occur to prevent organ rejection, but this may cause unwanted opportunistic infections including different parasitic, fungal, bacterial, and viral infections, particularly Herpesviridae members such as
4 Marzieh Jamalidoust et al/experimental and Clinical Transplantation (2015) Suppl 1: table 1. Characteristics of Patients with Posttransplant Lymphoproliferative Disorder Lesions Complication After Liver Transplant Patient Number Mean Viral Load (No. of Samples) Sex/Age (y) Underlying Disease Range of EBV Load PN1* - M/1 Tyrosinemia - PN (6) F/5 Tyrosinemia/HCC PN (2) F/1.5 Biliary atresia PN4* (5) F/1.5 Crigler-Najjar PN5* (8) F/2 Tyrosinemia PN (3) M/6 PFIC PN (5) F/9 Crigler-Najjar PN8* 0 (1) F/8-0 PN (4) F/5 Biliary atresia 0 PN (5) M/6.5 Crigler-Najjar Unclassified PTLD (n = 26) (76.4%) PN11 0 (1) M/22 Cryptogenic cirrhosis 0 PN12 - M/29 Cryptogenic cirrhosis - PN13* - M/51 HBV cirrhosis - PN14 - M/39 HCV cirrhosis - PN (9) F/3 Budd-Chiari PN16 - M/1.7 PFIC - PN17 - F/12 Crigler-Najjar - PN18 - M/2 Tyrosinemia - PN19 - F/0.10 Biliary atresia - PN20* - M/1.8 Crigler-Najjar - PN21 1 (0) F/9 Tyrosinemia 0 PN22 1 ( ) F/2.6 Biliary atresia PN23 - M/3 Neonatal hepatitis - PN24* - F/0.10 Crigler-Najjar - PN25 - F/3 Biliary atresia - PN26 - M/1.6 Neonatal hepatitis - PN27* - M/2 Biliary atresia - DLBCL (n = 5) (22%) PN28* - F/5 Tyrosinemia - PN29* 1000 (1) M/2 Biliary atresia - PN (1) F/8 Wilson 2300 PN (9) M/2 PFIC MALT n = 1 (4.3%) PN32 - F/16 Wilson - Non-Hodgkin lymphoma (n = 1) (4.3%) PN33 - M/2.5 Tyrosinemia - Hodgkin-lymphoma-type PTLD (n = 1) (4.3%) PN34* 0 (1) M/3 Tyrosinemia - Abbreviations: DLBLC, diffuse large B-cell lymphoma; EBV, Epstein-Barr virus; F, female; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; M, male; MALT, mucosa-associated lymphoid tissue; PFIC, progressive familial intrahepatic cholestasis; PTLD, posttransplant lymphoproliferative disorder *These patients died. cytomegalovirus, and EBV. 21 At present, it is proven that quantitative PCR is important in the early diagnosis of EBV-associated disorders, even several months before the onset of clinical manifestations. In the present study, according to the protocol in our center, EBV load was assessed in 127 suspected patients of 696 patients who received liver organ transplant between 2009 and The EBV loads in these patients were monitored 1 to 10 times after transplant, based on the clinical presentations. The data showed that the median of maximum viral loads were significantly higher in the PTLD patients (4035 copies/ml) than nonaffected patients (500 copies/ml), consistent with several previous studies. 3-5 As we detected in this study, a wide range of EBV loads were observed in liver transplant patients. This was because of involvement of multiple host factors such as age of transplant, active primary infection, different underlying disease, immunosuppressive drug regimen, and intensity. Therefore, it is more acceptable to monitor EBV load than consider a cutoff value to treat patients, as recommended in other studies In 8 PTLD patients who had serial viral loads available, large variation in maximum load (4370 to copies/ml) and time of maximum load ( d after transplant) were observed, which is consistent with other studies. 27,28 Infection with EBV causes a wide range of clinical manifestations including a nonspecific viral syndrome, infectious mononucleosis, and PTLD. 27,29 The PTLD, which is the most important EBVassociated disorder, can be prevented by modulation of the immune system, autologous expanded T-cell infusion, and/or use of anti-ebv drugs such as rituximab. 12,30 The incidence of PTLD in liver recipients in this study was 4.9% (34 of 696 patients); this is in agreement with other studies (1.6%-15%). In another study conducted in our center from 2003 to 2010, the incidence of PTLD was 0.9% (5 patients with PTLD in 550 liver transplant
5 310 Marzieh Jamalidoust et al/experimental and Clinical Transplantation (2015) Suppl 1: Exp Clin Transplant patients). 31 This difference may be explained by the use of more potent immunosuppressive regimens in the later years and higher index of suspicion of our clinicians to diagnose PTLD. The mortality of our patients with PTLD was high (11 of 34 patients [35%]), which is within the reported range of 15% to 55%. 32,33 High mortality indicates that current treatment modalities such as immunomodulation and antiviral therapy did not reverse the immunopathologic background that caused PTLD. 34 The mortality rate of PTLD among liver transplant recipients was somehow similar to those in previous report [11 of 696 patients (1.58%) vs (3 of 550 patients (0.54%)]. 31,35 As shown in several studies, the incidence of PTLD is higher in pediatric than adult liver transplant patients. 1-3 The Scientific Registry of Transplant Recipients (SRTR) reported that 82% PTLDs occur in children aged < 17 years. 36 In the current study, more than 88% (30 of 34 patients) of PTLD cases occurred in children aged < 12 years. This may have been caused by EBV seronegativity, primary infection occurring from a latent EBVinfected donor passenger leukocyte, or by close contact with healthy individuals in the community after transplant. 19,34 Although it is difficult to subcategorize PTLD lesions, 30,37 the most common PTLD lesion in our patients was monomorphic (5 of 34 patients), which is similar to data from other studies including a previous study in our center (3 of 5 patients). 30,31,37 A previous study reported that the monomorphic type occurred in 31%, polymorphic type in 19%, and hyperplastic form of early lesions in 1% patients. 38 Because the highest PTLD incidence and mortality were seen in pediatric liver transplant recipients, timely diagnosis of this complication before appearance of clinical symptoms is important. 29 Preventing PTLD by monitoring EBV loads after transplant should be considered, especially in infants, young children, and other patients who are at high risk of developing EBV infection. 39 References 1. Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBVassociated disease. Rev Med Virol. 2008;18(5): doi: /rmv Lieberman PM. Virology. Epstein-Barr virus turns 50. Science. 2014;343(6177): doi: /science Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev. 2010;23(2): doi: /CMR Schauer E, Webber S, Kingsley L, Green M, Rowe D. Increased Ignull B lymphocytes in the peripheral blood of pediatric solid organ transplant recipients with elevated Epstein-Barr viral loads. Pediatr Transplant. 2009;13(3): doi: /j x. 5. Cavallo R, Elia M, Gruosso V, Curtoni A, Costa C, Bergallo M. Molecular epidemiology of Epstein-Barr virus in adult kidney transplant recipients. Transplant Proc. 2010;42(7): doi: /j.transproceed Grywalska E, Markowicz J, Grabarczyk P, Pasiarski M, Roliński J. Epstein-Barr virus-associated lymphoproliferative disorders. Postepy Hig Med Dosw (Online). 2013;67: Tsai DE, Nearey M, Hardy CL, et al. Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant. 2002;2(10): Coppoletta S, Tedone E, Galano B, et al. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17 (6): doi: /j.bbmt Kullberg-Lindh C, Ascher H, Saalman R, Olausson M, Lindh M. Epstein-Barr viremia levels after pediatric liver transplantation as measured by real-time polymerase chain reaction. Pediatr Transplant. 2006;10(1): Rasche L, Kapp M, Einsele H, Mielke S. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant. 2014;49(2): doi: /bmt Xuan L1, Jiang X, Sun J, et al. Spectrum of Epstein-Barr virusassociated diseases in recipients of allogeneic hematopoietic stem cell transplantation. Transplantation. 2013;96(6): doi: / TP.0b013e31829d38af. 12. Loginov R, Aalto S, Piiparinen H, et al. Monitoring of EBV-DNAemia by quantitative real-time PCR after adult liver transplantation. J Clin Virol. 2006;37(2): Randhawa P, Demetris AJ, Pietrzak B, Nalesnik M. Histopathology of renal posttransplant lymphoproliferation: comparison with rejection using the Banff schema. Am J Kidney Dis. 1996;28(4): Randhawa PS, Magnone M, Jordan M, Shapiro R, Demetris AJ, Nalesnik M. Renal allograft involvement by Epstein-Barr virus associated post-transplant lymphoproliferative disease. Am J Surg Pathol. 1996;20(5): Carpentier L, Tapiero B, Alvarez F, Viau C, Alfieri C. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. J Infect Dis. 2003;188 (12): Green M, Cacciarelli TV, Mazariegos GV, et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation. 1998;66(12): Holman CJ, Karger AB, Mullan BD, Brundage RC, Balfour HH Jr. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transplant. 2012;26(5): doi: /j x. 18. Hess RD. Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J Clin Microbiol. 2004;42 (8): Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol. 2005;80(1): Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3): Larsen M, Habermann TM, Bishop AT, Shin AY, Spinner RJ. Epstein- Barr virus infection as a complication of transplantation of a nerve allograft from a living related donor. Case report. J Neurosurg. 2007; 106(5):
6 Marzieh Jamalidoust et al/experimental and Clinical Transplantation (2015) Suppl 1: Jang JY, Kim KM, Lee YJ, Lee SG, Chi HS. Quantitative Epstein-Barr virus viral load monitoring in pediatric liver transplantation. Transplant Proc. 2008;40(8): doi: /j. transproceed Ryan JL, Fan H, Glaser SL, Schichman SA, Raab-Traub N, Gulley ML. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffinembedded tissue and plasma. J Mol Diagn. 2004;6(4): Lee TC, Savoldo B, Rooney CM, et al., Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005;5(9): Capello D, Gaidano G. Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease. Mediterr J Hematol Infect Dis. 2009;1(2):e doi: /MJHID Wistinghausen B, Gross TG, Bollard C. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients. Pediatr Hematol Oncol. 2013;30(6): doi: / Hussein K, Tiede C, Maecker-Kolhoff B, Kreipe H. Posttransplant lymphoproliferative disorder in pediatric patients. Pathobiology. 2013;80(6): doi: / Baldanti F, Gatti M, Furione M, et al. Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell-depleted HLA-haploidentical stem cell transplantation. J Clin Microbiol. 2008;46(11): doi: /JCM Everly MJ, Bloom RD, Tsai DE, Trofe J. Posttransplant lympho - proliferative disorder. Ann Pharmacother. 2007;41(11): Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol. 2010;149(5): doi: /j x. 31. Geramizadeh B, Malek-Hosseini SA, Bahador A, et al. Posttransplantation lymphoproliferative disorder after liver transplantation: report of 5 cases among more than 550 liver transplants in Iran. Arch Iran Med. 2010;13(5): doi: / AIM Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol. 2001;19(3): Jain A, Nalesnik M, Reyes J, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg. 2002;236(4): Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013; 13(suppl 3): doi: /ajt Geramizadeh B, Nikeghbalian S, Dehghani SM, Bahador A, Salahi H, Malekhosseini S. Primary involvement of allografted liver in posttransplant lymphoproliferative disorders, report of two pediatric cases and review of the literature. Iran Red Crescent Med J. 2012;14(11): doi: /ircmj Leppke S, Leighton T, Zaun D, et al. Scientific Registry of Transplant Recipients: collecting, analyzing, and reporting data on transplantation in the United States. Transplant Rev (Orlando). 2013; 27(2): doi: /j.trre Mucha K, Foroncewicz B, Ziarkiewicz-Wróblewska B, Krawczyk M, Lerut J, Paczek L. Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant. 2010;25(7): doi: /ndt/gfq Allen U, Hébert D, Moore D, Dror Y, Wasfy S; Canadian PTLD Survey Group Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, : a Canadian multi-centre experience. Pediatr Transplant. 2001;5(3): Leung E, Shenton BK, Green K, et al., Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler. Transpl Infect Dis. 2004;6 (4):
Epstein-Barr Viral Load Before a Liver Transplant in Children With Chronic Liver Disease
ArtIcle Epstein-Barr Viral Load Before a Liver Transplant in Children With Chronic Liver Disease Nader Shakibazad, 1 Naser Honar, 1 Seyed Mohsen Dehghani, 2 Abdolvahab Alborzi 3 Abstract Objectives: Many
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationNephrology Grand Rounds
Nephrology Grand Rounds PTLD in Kidney Transplantation Charles Le University of Colorado 6/15/12 Objectives Background Pathogenesis Epidemiology and Clinical Manifestation Incidence Risk Factors CNS Lymphoma
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationDisclosures. CMV and EBV Infection in Pediatric Transplantation. Goals. Common Aspects CMV (Cytomegalovirus) and EBV (Epstein-Barr virus)
Disclosures I have financial relationships with the following companies: CMV and EBV Infection in Pediatric Transplantation Elekta Inc Lucence Diagnostics Spouse employed Spouse employed I will not discuss
More information2017 CST-Astellas Canadian Transplant Fellows Symposium. EBV Post Transplantation Implications and Approach to Management
2017 CST-Astellas Canadian Transplant Fellows Symposium EBV Post Transplantation Implications and Approach to Management Atul Humar, MD Atul Humar is a Professor in the Department of Medicine, University
More informationLeukaemia Section Short Communication
Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Leukaemia Section Short Communication Ding-Bao Chen Department of Pathology, Peking University People's Hospital,
More informationMeasurement of Epstein-Barr Virus DNA Loads in Whole Blood and Plasma by TaqMan PCR and in Peripheral Blood Lymphocytes by Competitive PCR
JOURNAL OF CLNCAL MCROBOLOGY, Nov. 2003, p. 5245 5249 Vol. 41, No. 11 0095-1137/03/$08.00 0 DO: 10.1128/JCM.41.11.5245 5249.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationLimitations of EBV PCR monitoring to detect EBV associated post-transplant lymphoproliferative disorder
Pediatr Transplantation 2003: 7: 223 227 Printed in UK. All rights reserved Copyright Ó 2003 Blackwell Munksgaard Pediatric Transplantation ISSN 1397-3142 Limitations of EBV PCR monitoring to detect EBV
More informationORIGINAL ARTICLE. Adenotonsillar Enlargement in Pediatric Patients Following Solid Organ Transplantation. solid organ transplantation is increasingly
Adenotonsillar Enlargement in Pediatric Patients Following Solid Organ Transplantation Robert Y. Huang, MD; Nina L. Shapiro, MD ORIGINAL ARTICLE Objective: To evaluate the management of adenotonsillar
More informationMatched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation
Rausch et al. Transplantation Research (2016) 5:6 DOI 10.1186/s13737-016-0036-1 RESEARCH Open Access Matched-pair analysis: identification of factors with independent influence on the development of PTLD
More informationLiver Transplant Pathology a general view
Liver Transplant Pathology a general view Dr S E Davies Addenbrooke s Hospital Cambridge University Hospitals NHS Trust ACP/BSG Meeting Leeds 2012 Liver transplantation When and where? Who and why? How?
More informationClinical characteristics, outcome and the role of viral load in nontransplant patients with Epstein Barr viraemia
ORIGINAL ARTICLE VIROLOGY Clinical characteristics, outcome and the role of viral load in nontransplant patients with Epstein Barr viraemia T. Martelius 1, M. Lappalainen 3,4, S. M. Aalto 3, A. Nihtinen
More informationOverall Goals and Objectives for Transplant Hepatology EPAs:
Overall Goals and Objectives for Transplant Hepatology EPAs: 1. DIAGNOSTIC LIST During the one-year Advanced Pediatric Transplant Hepatology Program, fellows are expected to develop comprehensive skills
More informationATA129 for Epstein-Barr virusassociated. lymphoproliferative disorder
March 2017 Horizon Scanning Research & Intelligence Centre ATA129 for Epstein-Barr virusassociated post-transplant lymphoproliferative disorder NIHR HSRIC ID: 10876 Lay summary ATA129 is a new treatment
More informationClassical Hodgkin lymphoma type PTLD
Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Leukaemia Section Review Classical Hodgkin lymphoma type PTLD Ding-Bao Chen Department of Pathology, Peking
More informationMore than 90% of adults worldwide have been infected
ORIGINAL ARTICLE Identifying Predictive Factors for Posttransplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients With Epstein-Barr Virus Viremia Lauren Weintraub, MD,* Chana
More informationEpstein-Barr Viral Load and Disease Prediction in a Large Cohort of Allogeneic Stem Cell Transplant Recipients
MAJOR ARTICLE Epstein-Barr Viral Load and Disease Prediction in a Large Cohort of Allogeneic Stem Cell Transplant Recipients S. M. Aalto, 1 E. Juvonen, 3 J. Tarkkanen, 2 L. Volin, 3 H. Haario, 4 T. Ruutu,
More informationMichael Grimley 1, Vinod Prasad 2, Joanne Kurtzberg 2, Roy Chemaly 3, Thomas Brundage 4, Chad Wilson 4, Herve Mommeja-Marin 4
Twice-weekly Brincidofovir (BCV, CMX1) Shows Promising Antiviral Activity in Immunocompromised Transplant Patients with Asymptomatic Adenovirus Viremia Michael Grimley 1, Vinod Prasad, Joanne Kurtzberg,
More informationEBV in HSCT 2015 update of ECIL guidelines
ECIL-6 EBV in HSCT 2015 update of ECIL guidelines Jan Styczynski (Poland, chair), Walter van der Velden (Netherlands), Christopher Fox (United Kingdom), Dan Engelhard (Israel), Rafael de la Camara (Spain),
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationAbstract. imedpub Journals Vol.3 No.2:12. Materials and Methods. Introduction
Research Article imedpub Journals http://www.imedpub.com/ DOI: 1.1/-.1 Epstein-Barr Virus DNA Viral Loads: Is There a Correlation Between Paired Whole Blood and Plasma Collected from a Cohort of Pediatric
More informationLiver Transplantation Status in Iran: A Multi-center Report on the Main Transplant Indicators and Survival Rates
Arch Iran Med. July 2018;21(7):275-282 http www.aimjournal.ir Original Article ARCHIVES OF IRANIAN MEDICINE Open Access Liver Transplantation Status in Iran: A Multi-center Report on the Main Transplant
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationPerformance of the Real-Q EBV Quantification Kit for Epstein-Barr Virus DNA Quantification in Whole Blood
Brief Communication Clinical Microbiology Ann Lab Med 2017;37:147-150 https://doi.org/10.3343/alm.2017.37.2.147 ISSN 2234-3806 eissn 2234-3814 Performance of the Real-Q EBV Quantification Kit for Epstein-Barr
More informationPlease submit supporting medical documentation, notes and test results.
Pharmacy Prior Authorization AETA BETTER HEALTH FLORIDA Valcyte (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.
More informationLack of Significant Co-Activation of BKV and CMV in Renal Transplant Patients: An Institutional Experience
Volume 1, Issue 1, pp: 1-6 Research Article Introduction Open Access Lack of Significant Co-Activation of BKV and CMV in Renal Transplant Patients: An Institutional Experience Minh-Thu Nguyen, BS 1, Phylicia
More informationTransplantation. Immunology Unit College of Medicine King Saud University
Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationEpstein Barr Virus Infection and Posttransplant Lymphoproliferative Disorder
American Journal of Transplantation 2013; 13: 41 54 Wiley Periodicals Inc. Continuing Medical Education C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons
More information/03/ /0 TRANSPLANTATION Vol. 75, , No. 7, April 15, 2003 Copyright 2003 by Lippincott Williams & Wilkins, Inc.
0041-1337/03/7507-1020/0 TRANSPLANTATION Vol. 75, 1020 1025, No. 7, April 15, 2003 Copyright 2003 by Lippincott Williams & Wilkins, Inc. Printed in U.S.A. THE ABSENCE OF CHRONIC REJECTION IN PEDIATRIC
More informationMulti-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant
Multi-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant Hanley PJ, Krance BR, Brenner MK, Leen AM, Rooney CM, Heslop HE, Shpall EJ, Bollard CM Hematopoietic Stem Cell Transplantation
More informationDiagnosis of CMV infection UPDATE ECIL
UPDATE ECIL-4 2011 Recommendations for CMV and HHV-6 management in patients with hematological diseases Per Ljungman, Rafael de la Camara, Hermann Einsele, Dan Engelhard, Pierre Reusser, Jan Styczynski,
More informationViruses. Poxviridae. DNA viruses: 6 families. Herpesviridae Adenoviridae. Hepadnaviridae Papovaviridae Parvoviridae
Viruses DNA viruses: 6 families Poxviridae Herpesviridae Adenoviridae Hepadnaviridae Papovaviridae Parvoviridae Human herpesviruses Three subfamilies (genome structure, tissue tropism, cytopathologic effect,
More informationPersistent Infections
Persistent Infections Lecture 17 Biology 3310/4310 Virology Spring 2017 Paralyze resistance with persistence WOODY HAYES Acute vs persistent infections Acute infection - rapid and self-limiting Persistent
More informationOutcomes of Liver Transplant for Biliary Atresia: A Ten Year Single Centre Experience
Outcomes of Liver Transplant for Biliary Atresia: A Ten Year Single Centre Experience Dr Yentl van Heerden; Dr Andrew Grieve, Professor Jerome Loveland For Paediatric Hepatobiliary and Liver Transplant
More informationAdenotonsillar Hypertrophy and Epstein-Barr Virus in Pediatric Organ Transplant Recipients
The Laryngoscope Lippincott Williams & Wilkins, Inc., Philadelphia 2001 The American Laryngological, Rhinological and Otological Society, Inc. Adenotonsillar Hypertrophy and Epstein-Barr Virus in Pediatric
More informationRisk factors for adenotonsillar hypertrophy in children following solid organ transplantation
International Journal of Pediatric Otorhinolaryngology (2003) 67, 151 /155 www.elsevier.com/locate/ijporl Risk factors for adenotonsillar hypertrophy in children following solid organ transplantation Nina
More informationSustained Epstein-Barr Virus Detection in Paediatric Liver Transplantation. Insights Into the Occurrence of Late PTLD
LIVER TRANSPLANTATION 13:343-348, 2007 ORIGINAL ARTICLE Sustained Epstein-Barr Virus Detection in Paediatric Liver Transplantation. Insights Into the Occurrence of Late PTLD Lorenzo D Antiga, 1 Monica
More informationVirological Surveillance in Paediatric HSCT Recipients
Virological Surveillance in Paediatric HSCT Recipients Dr Pamela Lee Clinical Assistant Professor Department of Paediatrics & Adolescent Medicine Queen Mary Hospital LKS Faculty of Medicine, The University
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationPost Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.
Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H. Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for
More informationMethotrexate-associated Lymphoproliferative Disorders
Methotrexate-associated Lymphoproliferative Disorders Definition A lymphoid proliferation or lymphoma in a patient immunosuppressed with methotrexate, typically for treatment of autoimmune disease (rheumatoid
More informationWithdrawal of Immunosuppression in Pediatric Liver Transplant Recipients in Korea
Original Article DOI 10.3349/ymj.2009.50.6.784 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 50(6): 784-788, 2009 Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients in Korea Jee
More informationSelected Abstracts Presented at the 14 th International Congress of Iranian Organ Transplantation Society (IRSOT)
Selected Abstracts Selected Abstracts Presented at the 4 th International Congress of Iranian Organ Transplantation Society (IRSOT) Does Urine Culture Result Predict Ureter Stent Culture Result in Patients
More informationPrevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients
TRANSPLANTATION Prevalence and Risk Factors of Recurrent Cytomegalovirus Infection in Kidney Transplant Recipients Mohsen Nafar, 1 Azamolsadat Roshan, 2 Fatemeh Pour-Reza-Gholi, 1 Fariba Samadian, 1 Pedram
More informationRAPID COMMUNICATION Preexisting malignancy is considered a relative contrain- dication to orthotopic liver transplantation (OLT) be-
RAPID COMMUNICATION Successful Outcome of Orthotopic Liver Transplantation in s With Preexisting Malignant States Sanjiv Saigal, Suzanne Norris, Parthi Srinivasan, Paolo Muiesan, Mohamed Rela, Nigel Heaton,
More informationKymriah. Kymriah (tisagenlecleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah
More informationEuropean Risk Management Plan. Measures impairment. Retreatment after Discontinuation
European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment
More information3/2/2010. Case 1. Clinical History. Infectious Disease Pathology Specialty Conference Case 1
Case 1. Clinical History Infectious Disease Pathology Specialty Conference Case 1 A 6 year-old girl with a large left neck mass. Past medical history: Biliary cirrhosis secondary to extra hepatic biliary
More informationAnne H. Blaes, 1,2 Qing Cao, 1 John E. Wagner, 1,3 Jo-Anne H. Young, 1,4 Daniel J. Weisdorf, 1,2 Claudio G. Brunstein 1,2
Monitoring and Preemptive Rituximab Therapy for Epstein-Barr Virus Reactivation after Antithymocyte Globulin Containing Nonmyeloablative Conditioning for Umbilical Cord Blood Transplantation Anne H. Blaes,
More informationWhat Is the Real Gain After Liver Transplantation?
LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom;
More informationA Single-Center Experience of Overseas Kidney Transplant for Immunologically High-Risk Patients
POSter PreSeNtAtION A Single-Center Experience of Overseas Kidney Transplant for Immunologically High-Risk Patients Cheol Woong Jung, 1* Kwan Tae Park, 2* Heungman Jun, 1 Su Yeon Kim, 3 Su Jin Kim, 3 Myung-Gyu
More information21/07/2017. Lymphoproliferations in immunodeficiency. IBD and EBV associated LPD in GIT Han van Krieken. Inflammatory bowel disease and cancer
IBD and EBV associated LPD in GIT Han van Krieken Lymphoproliferations in immunodeficiency Primary immunodeficiencies Large variation in conditions and lesions Acquired immunodeficiencies HIV: changes
More informationHEPATITIS B MANAGEMENT
HEPATITIS B MANAGEMENT Background Chronic Hepatitis B Virus (HBV) infection had an estimated prevalence in Australia of 0.7-0.8% in 2002 (1). Prevalence is highest in people born in much of Asia and Africa
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More informationImmune Cell Function Assay
Immune Cell Function Assay Policy Number: 2.04.56 Last Review: 12/2017 Origination: 12/2015 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for
More informationComparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
Jamalidoust et al. Virology Journal (2017) 14:127 DOI 10.1186/s12985-017-0797-2 RESEARCH Open Access Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit
More informationSample Selection- Vignettes
Sample Selection- Vignettes Rangaraj Selvarangan, BVSc, PhD, D(ABMM) Professor, UMKC School of Medicine Director, Microbiology, Virology and Molecular Infectious Diseases Laboratory Director, Laboratory
More informationEpidemiology of Posttransplantation Lymphoproliferative Disorder in Adult Renal Transplant Recipients
CLINICAL AND TRANSLATIONAL RESEARCH Epidemiology of Posttransplantation Lymphoproliferative Disorder in Adult Renal Transplant Recipients Muir Morton, 1 Beatrice Coupes, 1 Stephen A. Roberts, 2 Paul E.
More informationNon-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Supportive Care for NHL Tumor Lysis Syndrome (TLS) Laboratory hallmarks of TLS:
More informationHepatitis After Liver Transplantation: The Role of the Known and Unknown Viruses
Hepatitis After Liver Transplantation: The Role of the Known and Unknown Viruses Mario G. Pessoa,*00 Norah A. Terrault,*00 Linda D. Ferrell, Jill Detmer, Janice Kolberg, Mark L. Collins, Maurene Viele,
More informationTable of Contents (continued)
Emerging Molecular and Immunohematology Blood Typing, Grouping And Infectious Disease NAT Screening Assays And Companies Developing New Technologies and Products Table of Contents 1. Blood Typing and Grouping
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationResearch Article Anti-HLA and Anti-MICA Antibodies in Liver Transplant Recipients: Effect on Long-Term Graft Survival
Clinical and Developmental Immunology Volume 2013, Article ID 828201, 5 pages http://dx.doi.org/10.1155/2013/828201 Research Article Anti-HLA and Anti-MICA Antibodies in Liver Transplant Recipients: Effect
More informationEBV and Infectious Mononucleosis. Infectious Disease Definitions. Infectious Diseases
Infectious Disease Definitions Infection when a microorganism invades a host and multiplies enough to disrupt normal function by causing signs and symptoms Pathogencity ability of an organism to cause
More informationA clear path forward AVAILABLE NOW THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS
AVAILABLE NOW A clear path forward THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS AlloSure is the first and only non-invasive test that assesses organ
More informationPost-Transplant Lymphoproliferative Disorders
Post-Transplant Lymphoproliferative Disorders Vikas R. Dharnidharka Michael Green Steven A. Webber (Eds.) Post-Transplant Lymphoproliferative Disorders Vikas R. Dharnidharka, MD, MPH Associate Professor
More informationInt J Clin Exp Pathol 2014;7(1): /ISSN: /IJCEP
Int J Clin Exp Pathol 2014;7(1):438-442 www.ijcep.com /ISSN:1936-2625/IJCEP1310053 Case Report Epstein-Barr virus-related post-transplant lymphoproliferative disorder occurring after bone marrow transplantation
More informationInfectious Disease Pathology Specialty Conference Case 1
Infectious Disease Pathology Specialty Conference Case 1 Miguel Reyes Múgica, M.D. Department of Pathology Children s Hospital of Pittsburgh University of Pittsburgh Medical Center USCAP Annual Meeting.
More informationEBV Protocol
EBV Protocol 8.26.14 Data From UNOS Summary Stats 1988-2014 CASU + 2009-2014 CAPC Organ Total PTLD Percent PTLD Percent PTLD in Literature Heart 294 21 7 3-9 Heart-Lung 34 3 9 16 Intestine 42 7 17 10-45
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationImmune Reconstitution Following Hematopoietic Cell Transplant
Immune Reconstitution Following Hematopoietic Cell Transplant Patrick J. Kiel, PharmD, BCPS, BCOP Clinical Pharmacy Specialist Indiana University Simon Cancer Center Conflicts of Interest Speaker Bureau
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More informationDisclosure for Ralf Trappe, MD
Disclosure for Ralf Trappe, MD In compliance with ACCME policy, ASH requires the following disclosures to the session audience: Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau
More informationEpstein-Barr DNA Serology and Positron-Emission Tomography Imaging of the Head and Neck in Pediatric Transplant Recipients
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Epstein-Barr DNA Serology and Positron-Emission Tomography Imaging of the Head and Neck in Pediatric Transplant
More informationEBV infection B cells and lymphomagenesis. Sridhar Chaganti
EBV infection B cells and lymphomagenesis Sridhar Chaganti How EBV infects B-cells How viral genes influence the infected B cell Differences and similarities between in vitro and in vivo infection How
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationSingle donator specimens as advantage in external quality control assessments of infectious diseases
Single donator specimens as advantage in external quality control assessments of infectious diseases MD, PhD Maija Lappalainen and MD Jukka Suni HUSLAB, Department of Virology Labquality Days 10.2.2007
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More informationCellular Immunity to Epstein-Barr Virus in Liver Transplant Recipients Treated with Rituximab for Post-Transplant Lymphoproliferative Disease
American Journal of Transplantation 5; 5: 566 572 Blackwell Munksgaard Copyright C Blackwell Munksgaard 4 doi:./j.6-643.4.693.x Cellular Immunity to Epstein-Barr Virus in Liver Transplant Recipients Treated
More informationTranspla. antation. Associate Professor of Medical Virology Virology Research Center Shahid Beheshti University of Medical Sciences
Viral Mo olecular Diagno osis in Transpla antation Seyed Alireza Nadji, Ph.D. Associate Professor of Medical Virology Virology Research Center Shahid Beheshti University of Medical Sciences Which techniques
More informationHerpesviruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics
Herpesviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Virion Enveloped icosahedral capsid (T=16), diameter 125 nm Diameter of enveloped virion 200 nm Capsid
More informationUse of Viral Load Testing in Managing CMV Infections in SOTR
Use of Viral Load Testing in Managing CMV Infections in SOTR Angela M. Caliendo, MD, PhD, FIDSA Professor and Vice Chair, Medicine Alpert Medical School of Brown University Providence, RI Disclosures Scientific
More informationAppendix E1. Epidemiology
Appendix E1 Epidemiology Viruses are the most frequent cause of human infectious diseases and are responsible for a spectrum of illnesses ranging from trivial colds to fatal immunoimpairment caused by
More informationUsing Epstein-Barr Viral Load Assays To Diagnose, Monitor, and Prevent Posttransplant Lymphoproliferative Disorder
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2010, p. 350 366 Vol. 23, No. 2 0893-8512/10/$12.00 doi:10.1128/cmr.00006-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Using Epstein-Barr
More informationYescarta. Yescarta (axicabtagene ciloleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.105 Subject: Yescarta Page: 1 of 5 Last Review Date: September 20, 2018 Yescarta Description Yescarta
More informationVirus Reviews and Research
Virus Reviews and Research Sociedade Brasileira de Virologia journal homepage: www.sbv.org.br/vrr/ Research Article ACTIVE CYTOMEGALOVIRUS (CMV) INFECTION IN LIVER RECIPIENTS IN A HIGH CMV SEROPREVALENCE
More informationPosttransplant Lymphoproliferative Disorders in Liver Transplantation
ANNALS OF SURGERY Vol. 236, No. 4, 429 437 2002 Lippincott Williams & Wilkins, Inc. Posttransplant Lymphoproliferative Disorders in Liver Transplantation A 20-Year Experience Ashok Jain, MD,* Mike Nalesnik,
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationClinicalValidation Study of Quantitative Real-Time PCR Assay for Detection and Monitoring of BK Virus Nephropathy
Available online at www.annclinlabsci.org ClinicalValidation Study of Quantitative Real-Time PCR Assay for Detection and Monitoring of BK Virus Nephropathy 455 Satoru Kudose 1 and Jianli Dong 2 Departments
More informationTest Requested Specimen Ordering Recommendations
Microbiology Essentials Culture and Sensitivity (C&S) Urine C&S Catheter Surgical (excluding kidney aspirates) Voided Requisition requirements o Specific method of collection MUST be indicated o Indicate
More informationAdvances in gene encoding proteins of human herpesvirus 6
2009 9 4 3 Journal of Microbes and Infection, September 2009, Vol. 4, No. 3 165 6 1, 2 1., 241000; 2., 210029 : 6 ( HHV-6) DNA, HHV-6 80 100, ( IE) DNA DNA HHV-6 : 6 ; ; Advances in gene encoding proteins
More informationEBV Infection. > Cellular Immune Response Profiling. > Humoral Immune Response Profiling EBV. ImmunoTools
EBV ImmunoTools Peptide Tools to Study EBV EBV Infection > Cellular Immune Response Profiling Antigen spanning EBV PepMix Peptide Pools PepMix Collection EBV > Humoral Immune Response Profiling EBV RepliTope
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationChronic Infectious Mononucleosis/EBV Management
Chronic Infectious Mononucleosis/EBV Management Hypothesis Continuous or intermittent Epstein-Barr virus (EBV) replication after primary EBV infection causes tissue damage resulting in a myriad of symptoms.
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationCTYOMEGALOVIRUS (CMV) - BACKGROUND
CTYOMEGALOVIRUS (CMV) - BACKGROUND PURPOSE The flowing information provides guidance on the use of CMV negative blood components provided by the blood bank at the Royal Children s Hospital (RCH) including
More informationTopic BKV Polyoma Virus
Topic 13.1. BKV Polyoma Virus Author: Helen Pilmore and Paul Manley GUIDELINES a. We suggest screening high risk kidney transplant recipients for BK polyoma virus (BKV) with quantitative plasma NAT. The
More information